Clinical trial · Observational
Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma
Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma
NCT01171235CI-TRIAL-00003717unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to find for one or more serum or tissue markers of molecular biology in head and neck cancer patients used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Laryngeal Neoplasms | Laryngeal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pharyngeal Neoplasms | Pharyngeal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * all of nasopharyngeal carcinoma * hypopharyngeal carcinoma or laryngeal carcinoma visited at ENT department of NanFang hospital Exclusion Criteria: * all of above patients whose anticipated survival duration were less than 6 months
References
Publications (1)
- DERIVEDYu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang L, Li G, Chen HH, Li XP. MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. Int J Oncol. 2014 Apr;44(4):1215-22. doi: 10.3892/ijo.2014.2283. Epub 2014 Jan 28. PMID 24481647